₹583.05 on the BSE, up 10.85% from previous close. Favipiravir is an antiviral drug, which has shown potent in vitro activity against severe acute respiratory syndrome of coronavirus, the company said in a release.“We are pleased to add Favipiravir to our growing product portfolios.
The second wave is more aggressive and bigger in number than the first. We hope the availability of an effective treatment such as Favijaj will considerably ease the pressure, and offer patients much needed and timely therapy option," said Anil Jain, Joint Managing Director at Bajaj Healthcare.The company said it has developed the active pharmaceutical ingredient (API) and the formulation for favipiravir through its own in-house R&D team.“The drug controller of
Covid-19.rehab - the latest news concerning the spread of the SARS-CoV-2 coronavirus (formerly 2019-nCoV), as well as the infectious disease that it causes COVID-19, in separate countries and in the world as a whole. Current news on the topic of coronavirus SARS-CoV-2. Quarantine, pandemic 2020, epidemic: what is it, when will it come to end, precautions and how to protect yourself from this disease. The most honest news, no fakes! To keep up with the latest news, stay tuned for updates on the site! Every day we will collect news and statistics on coronavirus from around the world for you to be aware of this topic.
Owner: SNOWLAND s.r.o.
Registration certificate 06691200
16200, Na okraji 381/41, Veleslavín, 162 00 Praha 6